WO2008017894A1 - Peptide pour le traitement de l'asthme - Google Patents

Peptide pour le traitement de l'asthme Download PDF

Info

Publication number
WO2008017894A1
WO2008017894A1 PCT/GB2007/050488 GB2007050488W WO2008017894A1 WO 2008017894 A1 WO2008017894 A1 WO 2008017894A1 GB 2007050488 W GB2007050488 W GB 2007050488W WO 2008017894 A1 WO2008017894 A1 WO 2008017894A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
polynucleotide
agent
pharmaceutical composition
receptor
Prior art date
Application number
PCT/GB2007/050488
Other languages
English (en)
Inventor
Donna Elizabeth Davis
Allison-Lynn Andrews
John William Holloway
Original Assignee
University Of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southampton filed Critical University Of Southampton
Publication of WO2008017894A1 publication Critical patent/WO2008017894A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La présente invention concerne un peptide qui correspond à la séquence d'acides aminés de 17 mères du C-terminal cytoplasmique du récepteur de l'interleukine-13, l'IL-13Rα2, et des agents apparentés en tant qu'agents thérapeutiques utilisables en particulier pour le traitement de l'asthme et d'autres affections allergiques inflammatoires.
PCT/GB2007/050488 2006-08-10 2007-08-10 Peptide pour le traitement de l'asthme WO2008017894A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0615881A GB0615881D0 (en) 2006-08-10 2006-08-10 Novel peptide for treatment of asthma
GB0615881.0 2006-08-10

Publications (1)

Publication Number Publication Date
WO2008017894A1 true WO2008017894A1 (fr) 2008-02-14

Family

ID=37056125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050488 WO2008017894A1 (fr) 2006-08-10 2007-08-10 Peptide pour le traitement de l'asthme

Country Status (2)

Country Link
GB (1) GB0615881D0 (fr)
WO (1) WO2008017894A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020926A1 (fr) * 1995-12-06 1997-06-12 Sanofi Polypeptide recepteur de l'il-i3
WO1998010638A1 (fr) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Molecules d'interet therapeutique
WO2000064944A1 (fr) * 1999-04-28 2000-11-02 Genetics Institute, Inc. Traitement de la fibrose par antagonisme de il-13 et de chaines receptrices de il-13
WO2004019974A2 (fr) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccin
WO2005079755A2 (fr) * 2004-02-12 2005-09-01 Nektar Therapeutics Poudres antagonistes de l'interleukine-13, particules sechees par pulverisation, et procedes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020926A1 (fr) * 1995-12-06 1997-06-12 Sanofi Polypeptide recepteur de l'il-i3
WO1998010638A1 (fr) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Molecules d'interet therapeutique
WO2000064944A1 (fr) * 1999-04-28 2000-11-02 Genetics Institute, Inc. Traitement de la fibrose par antagonisme de il-13 et de chaines receptrices de il-13
WO2004019974A2 (fr) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccin
WO2005079755A2 (fr) * 2004-02-12 2005-09-01 Nektar Therapeutics Poudres antagonistes de l'interleukine-13, particules sechees par pulverisation, et procedes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREWS A-L ET AL.: "IL-4 receptor .alpha. Is an Important Modulator of IL-4 and IL-13 Receptor Binding: Implications for the Development of Therapeutic Targets", THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 12, 15 June 2006 (2006-06-15), pages 7456 - 7461, XP002457167, ISSN: 0022-1767 *
PENG Z ET AL.: "Novel Interleukin-13 Peptide-based Vaccine Downregulates Murine Allergic Airway Resonses", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 117, no. 2, February 2006 (2006-02-01), pages S250 - S251, XP002457118, ISSN: 0091-6749 *

Also Published As

Publication number Publication date
GB0615881D0 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
US11026994B2 (en) Syndecan-2 compositions and methods of use
US20180207270A1 (en) Methods of Using Interleukin-10 for Treating Diseases and Disorders
EP3047024B1 (fr) Compositions et méthodes destinées à traiter les maladies et les troubles auto-immuns et inflammatoires
Trivella et al. Structure and function of interleukin-22 and other members of the interleukin-10 family
EP1934353A2 (fr) Le domaine sushi de il-15ralpha comme enhancer sélectif et efficace de l'action de f il-15 grâce à il-15rbeta/gamma, et l'hyperagoniste (il15ralpha sushi -il15) comme protéine fusion
US20200277349A1 (en) N-terminally truncated interleukin-38
AU2016227322A1 (en) Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases
JP4887143B2 (ja) 癌細胞を選択的に死滅させるＲａｓＧＡＰ由来ペプチド
JP2022518262A (ja) ナチュラルキラー細胞を刺激するための組成物及び方法
Bittner et al. Soluble TL 1A is sufficient for activation of death receptor 3
JP2021512104A (ja) 癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ
JP2012511921A (ja) Ｃｘ３ｃｒ１受容体モジュレータ及びその治療的使用
US9403891B2 (en) Methods and compositions for modulating TNF/TNFR signaling
EP1263785A2 (fr) Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
JP4745224B2 (ja) 薬剤として有用なペグ化可溶性ｇｐ１３０二量体
AU2004308763A1 (en) Use of IL-18 binding protein in inflammations
WO2008017894A1 (fr) Peptide pour le traitement de l'asthme
JP2013523103A (ja) 融合タンパク質およびその使用
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
US20200308252A1 (en) Method for treating cd40-mediated diseases
ES2324306T3 (es) Uso de il-17f para el tratamiento y/o la prevencion de enfermedades neurologicas.
KR101950035B1 (ko) 세포투과성을 갖는 ｒ12 -ｐｉａｓ3 융합 펩타이드 및 이를 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물
WO2019168914A1 (fr) Cellules t modifiées par irf-4 et leurs utilisations dans le traitement du cancer
JP2013500029A (ja) 高い抗血管形成活性を示す変異体ｐｆ４ポリペプチド
WO2022078518A1 (fr) Molécule d'il-2 modifiée et utilisation associée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789374

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789374

Country of ref document: EP

Kind code of ref document: A1